ACE2 and cardiomyopathy: In this study, the therapeutic effects of ACE2 overexpression and cilazapril on doxorubicin-induced cardiomyopathy were first compared, and the results showed that treatment with cilazapril was able to reduce doxorubicin-induced cardiomyopathy, which are consistent with the cardioprotective effects of RAS blockade observed in models of doxorubicin-induced cardiomyopathy [47–49].